Investing.com - Canaccord Genuity initiated coverage on Pulse Biosciences Inc. (NASDAQ:PLSE) with a buy rating and set a price target of $32.00. The stock currently trades at $24.99, representing potential upside of roughly 28% to the analyst’s target. Shares have surged 88% over the past six months, though InvestingPro analysis suggests the stock is overvalued relative to its Fair Value estimate. Investors can explore more undervalued opportunities on the most overvalued stocks list.
The firm cited the company’s cardiac ablation platform as technically and clinically differentiated to meet the evolving needs of electrophysiologists. Pulse Biosciences uses a novel mechanism of action called nanosecond pulsed field ablation.
The technology builds on first-generation microsecond pulsed field ablation technology owned by large medical technology companies including Abbott Laboratories, Boston Scientific Corp., Johnson & Johnson, and Medtronic PLC. Pulse Biosciences’ nanosecond pulsed field ablation represents an evolution of the existing technology.
Canaccord said the company’s technology has shown early signs of differentiation that may lead to meaningful commercial adoption. The firm expects the advancement to improve both efficacy and clinical efficiency. According to InvestingPro Tips, analysts do not anticipate the company will be profitable this year, with revenue of just $0.75 million over the last twelve months. Want deeper insights? InvestingPro offers 13 additional tips for PLSE subscribers.
Pulse Biosciences develops a proprietary platform for clearing cells using its Nano-Pulse Stimulation technology in medical and non-medical applications.
In other recent news, Pulse Biosciences Inc. reported its Q1 2026 financial results, revealing an earnings per share (EPS) of -$0.27, which beat the forecasted -$0.30 by 10%. The company also met its revenue forecast, reporting $400,000 in revenue. Despite this positive earnings surprise, the stock experienced a decline, reflecting investor concerns over financial health and rising expenses. Additionally, two top executives, Co-Chairman of the Board Robert Duggan and Chief Executive Officer Paul LaViolette, acquired a combined 675,233 shares of the company’s common stock. This purchase, valued at approximately $13.3 million, was made through the company’s at-the-market equity offering program. These developments highlight significant insider confidence in the company’s prospects. Investors are closely monitoring these recent activities and financial results as they assess the company’s future trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates PLSE alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if PLSE is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?